|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Actemra
gptkb:interleukin-6
|
|
gptkbp:activities
|
IL-6 inhibition
|
|
gptkbp:appointed_by
|
intravenous infusion
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2010
gptkb:FDA
gptkb:EMA
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:contraindication
|
active infections
history of hypersensitivity
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Roche
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
tocilizumab
|
|
gptkbp:indication
|
gptkb:giant_cell_arteritis
gptkb:systemic_juvenile_idiopathic_arthritis
gptkb:COVID-19_pneumonia
gptkb:castle
|
|
gptkbp:influences
|
immune response
cytokine levels
inflammatory processes
|
|
gptkbp:ingredients
|
C6484 H10000 N1716 O2000 S44
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:warfarin
live vaccines
other immunosuppressants
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_available_on
|
vial
pre-filled syringe
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
lipid levels
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
gptkb:COVID-19
gptkb:rheumatoid_arthritis
cytokine release syndrome
|
|
gptkbp:manager
|
SC
IV
|
|
gptkbp:marketed_as
|
gptkb:Actemra
|
|
gptkbp:pharmacokinetics
|
half-life of 13 days
decrease in acute phase reactants
reduction of CRP levels
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
infectious diseases
pulmonary diseases
|
|
gptkbp:side_effect
|
headache
nausea
hypertension
rash
gastrointestinal perforation
increased risk of infections
infusion reactions
elevated liver enzymes
|
|
gptkbp:targets
|
gptkb:IL-6_receptor
|
|
gptkbp:weight
|
148 k Da
|